Clinical Trial Update: Alpha-synuclein in Cerebrospinal Fluid to Differentiate Alzheimer's Disease From Lewy Body Disease. [NA]

View source ↗

Summary

Clinical trial investigating alpha-synuclein in CSF to differentiate Alzheimer's disease from Lewy body dementia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Lewy Body Dementia

Snippet

Sponsor: University Hospital, Strasbourg, France | Conditions: "Alzheimer's Disease" and "Lewy Body Disease" | NA | Status: UNKNOWN